• DMX-200 ACTION3 phase 3 trial completed target recruitment of 286 adults patients
• Successful PARASOL collaboration data analysis outcome announced
• Dimerix received input from FDA on ACTION3 trial endpoints

During the quarter, Dimerix continued to focus on its lead product candidate DMX-200 through the ACTION3 Phase 3 clinical trial in FSGS. The company delivered a series of high-value clinical and regulatory milestones, including the full target recruitment of 286 adult patients, as well as continued dialogue with the FDA which reinforced proteinuria-based endpoints as suitable to support a full marketing approval pathway. Dimerix also announced the receipt of final data analysis under the PARASOL collaboration, which is expected to support potential marketing approval for DMX-200 in territories around the world. The company ended the quarter with a cash position of $38.5 million and remains well positioned to continue funding its operations, including the ongoing ACTION3 Phase 3 clinical trial. Dimerix continues to assess new R&D pipeline opportunities and pursue licensing opportunities with potential partners in territories not already licensed.

Dimerix may become eligible for up to ~AU$1.4 billion in total upfront payments and potential milestone payments, plus royalties on net sales, across all its licensing agreements, with over $65 million in total payments already being received.